News
NONOF
46.05
+6.20%
2.69
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
Seeking Alpha · 3d ago
The Market Is (Still) Underestimating Novo Nordisk
Seeking Alpha · 3d ago
Weekly Report: what happened at NONOF last week (0803-0807)?
Weekly Report · 5d ago
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion
Seeking Alpha · 08/07 22:29
Lilly, Novo antitrust case over GLP-1s dismissed in Texas
Seeking Alpha · 08/07 15:08
Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade
Seeking Alpha · 08/07 14:55
Stock Index Futures Gain With All Eyes on Key U.S. Jobs Report
Barchart · 08/07 05:26
Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
Seeking Alpha · 08/06 16:33
Lilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market
Seeking Alpha · 08/05 18:48
Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)
Seeking Alpha · 08/05 15:36
Eli Lilly jumps after Q2 beat driven by obesity drugs
Seeking Alpha · 08/05 11:30
S&P Futures Gain on Hopes for U.S.-Iran Deal; SpaceX and AMD Sink After Earnings
Barchart · 08/05 05:46
OPKO Health: Mazdutide And MDX-2201 Could Change Everything
Seeking Alpha · 08/04 17:55
Novo Nordisk slips despite lifting guidance on GLP-1 strength
Seeking Alpha · 08/04 17:16
Weekly Report: what happened at NONOF last week (0727-0731)?
Weekly Report · 08/03 09:47
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Seeking Alpha · 07/31 21:15
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
Seeking Alpha · 07/31 18:09
Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy
Seeking Alpha · 07/27 13:41
Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings
Seeking Alpha · 07/27 13:00
Weekly Report: what happened at NONOF last week (0720-0724)?
Weekly Report · 07/27 09:50
More
Webull provides a variety of real-time NONOF stock news. You can receive the latest news about Novo-Nordisk A S through multiple platforms. This information may help you make smarter investment decisions.
About NONOF
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.